Bringing together gynecological researchers from Washington, Oregon & British Columbia

Rivkin Center for Ovarian Cancer
8:00am - 8:30am  Check-in & Poster Set-up
8:30am - 8:40am  **Welcome: Kiran Dhillon, PhD, Rivkin Center for Ovarian Cancer**

**SESSION I: PREVENTION & EARLY DETECTION**

8:40am - 8:45am  **Intro: Charles Drescher, MD, Swedish Cancer Institute / Fred Hutch**

8:45am - 9:00am  **Garnet Anderson, PhD (Invited Speaker), Fred Hutch**
*Women’s Health Initiative and LILAC resources for gynecological cancers*

9:00am - 9:15am  **Van Nguyen, PhD, Fred Hutch**
*“Look” before you LEEP? An economic evaluation of the Pap see-and-treat strategy for the management of cervical pre-cancer*

9:15am - 9:30am  **Shannon Rush, MD, U. of Washington**
*Risk-reducing salpingo-oophorectomy: a single institutional experience in over 500 women at increased risk for ovarian carcinoma*

9:30am - 9:45am  **Jeffrey Krimmel-Morrison, MD, U. of Washington**
*Deep sequencing of pap smears reveals low-frequency somatic TP53 mutations in women with and without serous ovarian cancer*

9:45am - 10:05am  **Panel Discussion & QA: Moderator Charles Drescher, MD**

10:05am - 10:30am  **Coffee Break (B-72/74/76)**

**SESSION II: CANCER BIOLOGY & MECHANISMS**

10:30am - 10:35am  **Intro: Rosana Risques, PhD, U. of Washington**

10:35am - 10:50am  **Denise Galloway, PhD (Invited Speaker), Fred Hutch**
*HPV oncoproteins disrupt the repair of DNA damage*

10:50am - 11:05am  **Talayeh Ghezelayagh, MD, U. of Washington**
*Gain-of-function and loss-of-function TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations*

11:05am - 11:20am  **Maria Isabel Harrell, PhD, U. of Washington**
*Development and implementation of a targeted next generation sequencing methylation panel for the assessment of methylation in ovarian and endometrial cancers*

11:20am - 11:35am  **Dawn Cochrane, PhD, British Columbia Cancer Agency**
*The origins of endometriosis associated cancers*

11:35am - 11:50pm  **Aline Talhouk, PhD, U. of British Columbia**
*Validation of ProMisE molecular classifier in a large population based series: a new era in endometrial carcinoma diagnosis and treatment*

11:50pm - 12:10pm  **Panel Discussion & QA: Moderator Rosana Risques, PhD**
SESSION III: SHORT POSTER PRESENTATIONS 1
12:10pm – 12:20pm Short poster presentations
12:20pm - 2:00pm Lunch & Posters (B-72/74/76)

SESSION IV: CANCER THERAPY
2:00pm - 2:05pm Intro: Elizabeth Swisher, MD, U. of Washington / Seattle Cancer Care Alliance
2:05pm - 2:20pm Gordon Mills, MD/PhD (Invited Speaker), Knight Cancer Institute Systems approach to rational combination therapy
2:20pm - 2:35pm Marta Llaurado, PhD, U. of British Columbia Proteomic biomarkers of MEK inhibitor resistance in low-grade serous ovarian cancer cell lines
2:35pm - 2:50pm Franz Schaub, PhD, SEngine Precision Medicine Personalized medicine: A CLIA-certified high-throughput drug screening platform for ovarian cancer
2:50pm - 3:05pm Yemin Wang, PhD, U. of British Columbia Targeting strategies for small cell hypercalcemic carcinoma of the ovary, hypercalcemic type (SCCOHT)
3:05pm - 3:25pm Panel Discussion & QA: Moderator Elizabeth Swisher, MD
3:25pm - 3:50pm Coffee Break (B-72/74/76)

SESSION V: SHORT POSTER PRESENTATIONS 2
3:50pm – 4:00pm Short poster presentations

SESSION VI: IMMUNOTHERAPY
4:00pm - 4:05pm Intro: Nora Disis, MD, U. of Washington / Fred Hutch
4:05pm - 4:20pm Brad Nelson, PhD (Invited Speaker), British Columbia Cancer Agency Tumor infiltrating lymphocyte (TIL) patterns in ovarian & endometrial cancers
4:20pm - 4:35pm Kristin Anderson, PhD, U. of Washington / Fred Hutch Engineering immunosuppressive pathways operative within T cells for enhancing adoptive therapy of ovarian cancer
4:35pm - 4:50pm Denise Cecil, PhD, U. of Washington Vaccine targeting antigens associated with epithelial to mesenchymal transition in combination with cisplatin significantly inhibits ovarian cancer growth
4:50pm - 5:05pm Christopher Morse, MD, U. of Washington / Fred Hutch Adoptive T cell therapy for ovarian cancer: Development of a surgically relevant model
5:05pm - 5:25pm Panel Discussion & QA: Moderator Nora Disis, MD
5:25pm - 5:30pm Closing Remarks: Kiran Dhillon, PhD, Rivkin Center for Ovarian Cancer
5:30pm - 7:00pm RECEPTION (B-72/74/76)
POSTERS

Michael Anglesio, PhD, U. of British Columbia
*Advanced methods for cancer detection by vaginal screening: feasibility and assessment of deep sequencing based self-sampling methods*

Tara Coffin, U. of Washington
*MAGENTA: a large randomized study to define an optimal genetic counseling strategy in women undergoing genetic testing at home for ovarian cancer risk*

Jamie Crase, U. of Washington
*The central role of advocates on the Stand up To Cancer Ovarian Cancer Research Fund Alliance - National Ovarian Cancer Coalition Ovarian Cancer Dream Team*

Soledad Jorge, MD, U. of Washington
*Disease course and treatment patterns of unselected patients with ovarian carcinoma and germline BRCA mutations*

Toni Jun, PhD, Crown Biosciences Inc.
*Establishment and characterization of human ovarian cancer xenograft models using bioluminescence imaging*

Marilyne Labrie, PhD, Knight Cancer Institute
*Adaptive response of ovarian cancer cells to PARP and DNA damage checkpoint inhibitors*

Barbara Norquist, MD, U. of Washington, Seattle, WA
*WISP: a surgical prevention study evaluating bilateral salpingo-oophorectomy versus interval salpingectomy and delayed oophorectomy in women with inherited mutations in ovarian cancer susceptibility genes*

Marc Radke, U. of Washington
*Somatic reversion mutations in hereditary ovarian carcinomas predict platinum sensitivity*

Chaoyang Sun, PhD, Knight Cancer Institute
*BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency*

PLANNING COMMITTEE

Brad Nelson, PhD, British Columbia Cancer Agency
Charles Drescher, MD, Swedish Cancer Institute / Fred Hutch
Elizabeth Swisher, MD, University of Washington / Seattle Cancer Care Alliance
Kiran Dhillon, PhD, Rivkin Center for Ovarian Cancer
Nora Disis, MD, University of Washington / Fred Hutch
Rosana Risques, PhD, University of Washington

SPONSORS

www.rivkin.org | 801 Broadway Ste, 701, Seattle, WA 98122